8-K
NEUROCRINE BIOSCIENCES INC false 0000914475 0000914475 2020-07-13 2020-07-13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 13, 2020

 

NEUROCRINE BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

Delaware

 

0-22705

 

33-0525145

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

     

12780 El Camino Real,

San Diego, California

 

92130

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 617-7600

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol

 

Name of each exchange on which
registered

Common Stock, $0.001 par value

 

NBIX

 

Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 


Item 8.01. Other Events.

On April 27, 2020, Neurocrine Biosciences, Inc. (the “Company”) announced that once-daily oral ONGENTYS® (opicapone) 25 mg and 50 mg capsules received approval from the U.S. Food and Drug Administration (FDA) as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes. The Company has established the wholesale acquisition cost (“WAC”) for a 30-count bottle of ONGENTYS 25 mg capsules or 50 mg capsules at $590. The Company continues to prepare for the commercial launch of ONGENTYS which is expected to occur later in 2020.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

NEUROCRINE BIOSCIENCES, INC.

             

Date: July 13, 2020

 

 

   

 

/s/ Darin M. Lippoldt

 

 

 

Darrin M. Lippoldt

 

 

 

Chief Legal Officer

v3.20.2
Document and Entity Information
Jul. 13, 2020
Cover [Abstract]  
Entity Registrant Name NEUROCRINE BIOSCIENCES INC
Amendment Flag false
Entity Central Index Key 0000914475
Document Type 8-K
Document Period End Date Jul. 13, 2020
Entity Incorporation State Country Code DE
Entity File Number 0-22705
Entity Tax Identification Number 33-0525145
Entity Address, Address Line One 12780 El Camino Real
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code (858)
Local Phone Number 617-7600
Security 12b Title Common Stock, $0.001 par value
Trading Symbol NBIX
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false